Doctor Explains GLP 1 Blindness Risk (Should You Be Worried?)

Added: 2026-05-19

[00:00:00]If you're taking a GLP1 medication or you're thinking about starting one of these puppies, you probably have heard, how could you not, something about blindness. I mean, that's a freaking big massive deal. You don't just ignore that. Oh, I'm not going to worry about blindness, blah blah blah blah. No, it's going to jolt and impinge on you. The sad reality of what you're seeing out there is far from the real data. And so, that's what I want to break down in this video is sift the truth from the BS. And more importantly, I'm going to teach you how to minimize the real risk in addition to just giving you the actual understanding of what the real risk is because there's a lot of misinformation out there and I want to help clear the air. I'm Dr. Jones DC and I've lost 100 pounds myself. I've coached thousands of patients through this therapy. Now, I'm not an opthalmologist and I don't write your prescriptions. But my job though is to translate what your eye doctor and your prescribers aren't explaining to each other or to you probably for that matter. And over the next couple minutes, I'm going to separate real risk from the fear-mongering stuff that's happening. And boy oh boy, is there a lot of fear-mongering so you'll understand whether you're one of the actual people who needs to worry or one of the people who can just breathe and continue using your GLP1s and do your thing. Okay. So before we talk numbers though, you have to understand what you're actually afraid of because most of what people are calling GLP1 blindness online isn't what's in the data. So the condition being studied is called N A I O N or non-arthritic eskeemic optic neuropathy. Basically it's a stroke of the nerve that feeds your eyeball. The optic nerve is the cable that connects your brain to your eyes. Thousands of tiny little fibers bundled together running through a narrow tunnel in your skull. In some people that tunnel is a little smaller than average. The cable is a little more crowded. Eye doctors call this the disc at risk anatomy. And it's something that you were born with or you weren't. And here's why this matters. Because when blood flow to that nerve gets briefly compromised and various factors can contribute to that the nerve it swells and in a crowded tunnel there's nowhere for it to swell which can create a compartment-like effect that ultimately damages the nerve and much of the vision in that eye is often permanently lost.

[00:02:04]That's what nonarththoritic eskeemic optic neuropathy is. And I want to be really clear about what it's not because a lot of you watching have been noticing some kind of vision change on these medications and you're assuming the worst. Blurry vision that comes and goes on GLP-1s is often blood sugar fluctuation affecting the lens of your eye and it typically resolves as glucose stabilizes. Dry, irritated eyes from being more dehydrated than usual. That's dehydration. Distance vision getting slightly worse over months, that's aging or something called refractive change.

[00:02:35]None of these things are n a n. This condition is sudden and it often happens overnight. People wake up with it. One eye, one sector of the visual field, often with lasting loss. It is a specific mechanical event in a specific anatomy that most people aren't carrying the setup for. And here's the part that comes back later. Your eye doctor can look at the back of your eye and tell you if you have a disc at risk setup.

[00:02:58]Which camp you're in is going to matter for everything that's coming next. And by the way, if you're sitting here realizing that you don't really know if you should be approaching your GLPM medications after learning all this stuff, we offer a free discovery call with our patient educators where they can help you think through your total situation, what your journey is like, and more importantly, what it's like to work with me or my coaches so that we can help structure a safe program, and more importantly, one that gets you results long term. You can text number on the screen or check out the link in the description if you want to explore that. But first, let's go over the numbers because the numbers are where the real picture comes together. So in the general population, estimates range from about 1 to 10,000 to 1 in 50,000 adults per year. Now that rate climbs with age and that's the baseline in adults on a GLP1. One major database study put that number somewhere closer to 1 in 2700 adults. Of course estimates are going to vary across studies. Now, I think it's important to talk about the fact that partial blindness is such a debilitating issue that if it happens to you or any other loved one, there's an immediate frame where the stats and the probability of it actually happening completely are just out of sight and all of a sudden you're stuck on the fact that this is going to happen to everybody else. But that's why I'm doing this video because while it is awful and I'm going to teach you guys how to minimize your risk, I think it's important to take a step back and realize that the stats are the stats and that's the real risk. And we're going to cover those too as well so that you guys understand what the real risk is versus what you might think it is and where emotion might impact that. It's also important to know that this risk isn't evenly distributed across time. So early reports suggest that NI cases cluster in the window when patients hit and sustain maximum doses. For most patients on standard titration schedules, that lands somewhere in the first couple years on the therapy. So if you've been on a GLP1 for three, four, five years, you're well past the window where most of the documented cases appeared. You are not accumulating risk the way that the headlines make it sound like you are.

[00:04:51]And not every GLP1 shows the same signal. Some for example is where most of the current signal sits. That's ompic and waggoi. The data on other GLP1s is still emerging. Then there's trezepide, mjaro, and zepound. It doesn't show the same signal yet, though it's only been on the market for a couple years, so it's too early to say definitively. And with some glutide, there's one pattern that stands out. Early reports suggest WGOi, the higher dose weight loss version, shows a stronger signal than the lower dose versions of Zmpic. The exact magnitude though is still being sorted out. Now, that's a dose story and we're going to come back to that in a minute because that's crucial and that's how I'm going to teach you how to minimize your risk. Now, we have to talk about the other side of the ledger here, what these medications are actually preventing because that's the number that you have to weigh this against.

[00:05:34]Okay, so let's start with comparing the risks and what you're going to lose if you stop the medication, right? Because there's a benefit to being on these medications that I'm arguing is significantly more than this. I want us to get into this one in 2,700 cases, which is the worst of of what we said, but I'm going to go ahead and give that to you. But then this is crucial because we know heart attack risk decreases. Stroke risk decreases.

[00:06:01]Deaths mortality flat out they're prevented. So let me map this out. On one side of the ledger we have a risk of one in 2700 shot of getting this condition. The other side what these medications are actually preventing. And this column is bigger for a reason. The select trials looked at saglutide in adults with obesity and cardiovascular risk. A 20% reduction in heart attacks, strokes and cardiovascular death. A broader metaanalysis in people with obesity without diabetes found roughly a 20% reduction in major cardiovascular events. So you're not comparing drug risk to zero risk. You're comparing a small clustered anatomy dependent risk of this condition Nao N against a well doumented reduction in the things that actually kill most adults. And the condition that these drugs are treating, insulin resistance, type two diabetes, obesity is itself the leading cause of blindness. That untreated disease has its own eye problems. That's what actually changes if you stop. The ledger leans hard in the other direction. Now, by the way, real quick, if that reframe just landed, do me a solid and hit that subscribe button because we put out two GLP-1 videos every single week with the same calibrated approach. No fear-mongering, no cheerleading, just the actual math on what works and what's worth your attention. and be sure to hit that bell. Okay, so what actually falls into that 1 in 2700? So number one, we have the disc at risk anatomy, the crowded tunnel setup that we talked about earlier. Your eye doctor can check for this. Number two, existing eye conditions, gluccom, prior optic nerve injury, anything that's already stressed that nerve may add vulnerability. Number three, age over 50 with high blood pressure, diabetes, or sleep apnea.

[00:07:38]Those conditions all affect small blood vessel flow, including the blood flow to your optic nerve. Number four, the window when you hit and sustain maximum dose. Remember that's almost always in the first one to two years. Number five, and this is where things get interesting, the dose that you're on and how fast you got there. The onlabel GLP-1 titration schedule is designed to escalate patients to maximum dose in about four to 5 months. Though many clinicians adjust that in practice, which means under the center protocol, the peak exposure lands early and it stays there. That's when the Ni signal is the hottest. The protocol itself is part of the risk profile. It's the dose escalation trap, automatic titration that pushes you up the dose ladder without asking whether you actually need to keep climbing. So here's the part that matters most. You don't need maximum dose to lose weight. And in our clinic, the patients who I coach through GLP-1 therapy, they rarely go above 75 to 1 milligram of saglutide, five7 milligrams of turseptide or maybe four, five of reup. Not because those high doses are inherently bad. there are people that need them because most of our patients are already hitting their goals on lower doses because we're implementing strategic lifestyle interventions. You see, there's a window where the medication is doing its job and above that window, you're paying the exposure cost without much more benefit.

[00:08:56]That's the therapeutic window and the sweet spot in action. Across the thousands of patients we've coached on this lowest effective dose approach, tracked over years with baseline exams and symptom monitoring, we haven't seen a single case. Now, that's observational. The Naio N condition itself is rare enough that a single clinic's zero case record isn't proof of protection, but it's certainly consistent with what the exposure math would actually predict. Okay, the simple version here, the standard protocol is the risk profile. The lowest effective dose is the mitigation. Quick minute, I want to tell you guys about the flow academy membership. Essentially, this is my private community on Mighty Networks.

[00:09:32]You'll have access to a community coach, live coaching calls that I do, which are unsolicited. I don't have to market like my free lives. I'm just there to help you guys out as much as possible and a ton of free resources as well to guide you through the various protocols that I talk about in these videos. So, all you got to do if you're interested in joining that is just become a member to this YouTube page and then there's a link that you can access after you become a member that'll allow you to join the community. Now, back to the video. Now, if you want a full video on exactly how we run the lowest effective dose protocol, the dosing math, how we time titration, why most patients never escalate to the max, let me know in the comments if that would be helpful to you. Okay, so what do you actually do with all of this? First up, know the red flag symptoms. Sudden vision change in one eye is the one to pay attention to.

[00:10:14]A section of your visual field going blank or gray. Some patients describe it as seeing the outline of a shape like a cupcake shape instead of the whole image. Colors looking washed out in one eye but not the other. These are not wait and see symptoms. These are call your eye doctor today symptoms. Evaluate as soon as possible, ideally the same day. Number two, three questions to ask your eye doctor. Number one, can you do a baseline dilated exam and document whether you have a disc at risk anatomy situation? That tells you which camp you're in. Number two, if I develop any symptoms, can you do an OCT, an optical coherence tomography of my optic nerve?

[00:10:51]That's the key imaging tool. If something changes, usually combined with a dilated exam and visual field testing.

[00:10:57]And then number three, given my condition and my other conditions and what you see on my exam, what's your honest read at my risk? Now, many of you have told me that your eye doctor was more worried than your prescriber or the other way around. You deserve a real answer from someone who's looked at your actual eye. And speaking of that disconnect, if you've had that experience, let me know in the comments when your eye doctor is more worried than your prescriber or the other way around because other people reading this will know that they're not alone in this. And now the hardest move, the one a lot of you are considering that I'd actually push back on. Don't stop the medication cold turkey. I know that sounds counterintuitive after everything that we've just covered. Think about the ledger here for a second. Okay, so this is important and I've already mentioned it, but we have the weight regain plus the metabolic rebound. Stopping suddenly can cost you the cardiovascular protection and that benefit depends on staying on the treatment. It sets up metabolic rebound.

[00:11:59]Your appetite comes roaring back and many patients regain a substantial amount of the weight over the following year. And I know a lot of you are thinking right now, okay, if I shouldn't stop cold turkey, then how do I eventually taper off safely? That's a whole separate video. If you want me to make that video, let me know in the comments and I'll film the whole protocol, the dose step downs, the timing, how to avoid weight regain, the whole thing. Okay. So, if you are going to stop or switch, do it with your prescriber and your eye doctor working together, not as a solo decision after a little Tik Tok video. Even the Neuroopthalmology Society that studies this condition has put out a statement.

[00:12:31]Do not discontinue GLP1s based on Naio N fear alone. The first 6 to 12 months on a GLP1 is also the foundation window. A powerful stretch when your appetite and eating patterns can reset and new habits have a chance to lock in. And when your relationship with food can reorganize, it overlaps the window where Naio N cases cluster. Stopping inside it doesn't just expose you to cardiovascular rebound. It wastes the biggest opportunity that these medications give you. Okay, so this is what you're starting to hopefully think with max dose equals higher risk. Now, we can just ignore that because we don't do the highest risk here. But what we do do lower dose lower risk and I would argue almost nonexistent.

[00:13:27]So we also have the weight regain plus the metabolic rhythm. Okay. So the move isn't stopping. The move is navigating with the right dose, the right monitoring, and the right team. Now, before we wrap up, where do you actually land on all of this? Because if everything that I just covered made you realize what you actually need is that team, not a script and ship prescriber, not a Google search at 2 a.m., we offer free discovery calls with our patient educators. They're going to hear you out on your history, what you've tried, and what's on your mind going forward. You'll get a feel for working with me, the coaches, and our medical team. And then they're going to walk through programs and pricing so that you can picture what a supervised year actually looks like. You can text somewhere on the screen or check out the link in the description if you want to book that. Another important thing that many GLP1 users get wrong is how to maximize their results simply by injecting. So check out that video right there where I break down what the research says of how to actually approach injecting in a way to maximize results. It's a super easy lever to pull on. So take advantage of that. We'll see you later.